Literature DB >> 2174853

The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin.

M A Cooper1, K Nye, J M Andrews, R Wise.   

Abstract

The pharmacokinetics of azithromycin were determined during a 24 h period following oral administration of a single 500-mg dose to each of six male volunteers. Concentrations in serum, urine and cantharides-induced inflammatory fluid were determined by microbiological assay. The mean peak serum concentration of 0.45 mg/l was obtained at a mean time of 2.6 h post-administration. The elimination half-life from serum was seen to increase with time post-dose; the mean elimination half-life at 16 h post-dose was 9.6 h. Inflammatory fluid was penetrated rapidly, with the mean peak concentration of 0.13 mg/l achieved at a mean time of 3.25 h post-dose. After this peak, levels initially decreased, but after 8 h from drug administration until the end of the trial period, inflammatory fluid concentrations remained relatively constant. The mean inflammatory fluid penetration up to the end of the study period was 74%. The mean urinary recovery of azithromycin, during the initial 24 h post-dose, was 6%.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174853     DOI: 10.1093/jac/26.4.533

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species.

Authors:  M H Nguyen; C J Clancy; Y C Yu; A S Lewin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

Review 2.  The pharmacokinetics of azithromycin and their clinical significance.

Authors:  H Lode
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 3.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

4.  Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid.

Authors:  C D Freeman; C H Nightingale; D P Nicolau; P P Belliveau; M A Banevicius; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.

Authors:  Kensuke Shima; Márta Szaszák; Werner Solbach; Jens Gieffers; Jan Rupp
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

7.  Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors:  D A Stamler; M A Edelstein; P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition.

Authors:  J P Chave; A Munafo; J Y Chatton; P Dayer; M P Glauser; J Biollaz
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 10.  Azithromycin clinical pharmacokinetics.

Authors:  N J Lalak; D L Morris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.